Publications by authors named "Yuichiro Tada"
Background/aim: The predictive role of hematological markers in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with pembrolizumab remains unclear.
Patients And Methods: We conducted a multicenter retrospective cohort study to investigate the predictive impact of the pre-treatment hematological markers neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CRP-albumin-lymphocyte (CALLY) index, and the modified Glasgow prognostic score (mGPS) on overall survival (OS) and progression-free survival (PFS) in patients with R/M SCCHN treated with pembrolizumab. From December 2019 to February 2022, 119 and 28 patients were treated with pembrolizumab alone and pembrolizumab plus chemotherapy, respectively.
Article Synopsis
- Pembrolizumab, an immune checkpoint inhibitor, shows effectiveness in treating recurrent and metastatic salivary gland carcinoma (SGC), but no predictive biomarkers for its efficacy have been established prior to this study.
- A study involving 27 patients identified optimal cut-off values for the combined positive score (CPS) and tumor proportion score (TPS) of PD-L1, which were found to significantly predict treatment outcomes.
- The overall response rate for SGC was 25.9%, with higher response rates in patients with high CPS and TPS, and a lower platelet-lymphocyte ratio correlated with improved progression-free survival, while the treatment demonstrated a good safety profile with no severe adverse events.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rapidly progressive cancer-related disease with a dismal clinical course. The patient in this report was a 43-year-old man with metastatic salivary duct carcinoma arising from the parotid gland. Combined androgen blockade therapy was administered started as first-line treatment, but failed after 5 months, followed by docetaxel plus carboplatin therapy as second-line treatment, which failed after 3 months.
View Article and Find Full Text PDFMany researchers have focused on the role of the autonomic nervous system in the tumor microenvironment. Autonomic nerves include the sympathetic and parasympathetic nerves, which are known to induce cancer growth and metastasis. However, in salivary duct carcinoma (SDC), a rare and highly malignant tumor, the issue should be investigated from both biological and therapeutic perspectives.
View Article and Find Full Text PDFBackground: Trastuzumab treatment for salivary gland, gastric, and breast cancer commonly causes cancer treatment-related cardiac dysfunction (CTRCD). CTRCD incidence by sex has not been well studied.
Methods: This retrospective cohort study investigated frequency of and sex differences in CTRCD in patients with salivary gland cancer treated with trastuzumab at our hospital from April 2017 to March 2022.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of apalutamide combined with goserelin for treating androgen receptor-positive unresectable or metastatic salivary gland carcinoma.
- A total of 31 patients were enrolled, but only 25% of the first 24 patients responded to the treatment, which did not meet the expected effectiveness criteria; however, the clinical benefit rate was 50%.
- The treatment demonstrated potential benefits in a subgroup of patients with high AR positivity (≥70%) and reported side effects were in line with what’s typically observed in prostate cancer treatments.
High-grade carcinomas of the salivary glands are a group of several tumor entities with highly malignant histologic appearances, and have an aggressive biological behavior accompanied by poor a prognosis. In general, they require more intensive treatment than low- or intermediate-grade carcinomas. High-grade salivary carcinomas are rare and the microscopic features often overlap between different tumor types, making an appropriate diagnosis challenging in daily practice settings.
View Article and Find Full Text PDFArticle Synopsis
- Photoimmunotherapy (PIT) involves administering cetuximab sarotalocan sodium followed by laser light treatment, targeting tumors that express the epidermal growth factor receptor, particularly for advanced head and neck cancer.
- While standard treatments like radiotherapy and chemotherapy are preferred, airway emergencies from pharyngeal edema are a significant concern, often leading to prophylactic tracheostomy.
- A case study revealed a patient with nasopharyngeal carcinoma who developed airway narrowing and needed emergency tracheostomy after PIT, emphasizing the importance of monitoring for potentially life-threatening airway complications.
Article Synopsis
- Salivary duct carcinoma (SDC) has a low 5-year survival rate of 40%, and the impact of brain metastasis (BM) on patient outcomes is not well understood.
- A study of 464 SDC patients revealed that 14% had BM, with a median overall survival (mOS) of 13.1 months, and several factors linked to poorer survival, including performance status and uncontrolled disease.
- A new prognostic tool, the SDC-graded prognostic assessment (GPA) score, shows varying mOS estimates based on different scores, demonstrating its effectiveness in estimating outcomes for patients with BM.
Article Synopsis
- Adenoid cystic carcinoma (AdCC) of the salivary gland is a slow-growing cancer that can sometimes spread to distant sites, although not commonly through lymph nodes.
- A study of 175 patients without lymph node metastasis identified key prognostic factors that influence disease free survival (DFS), distant metastasis free survival (DMFS), and overall survival (OS), particularly focusing on positive surgical margins and tumor stage.
- The findings showed that patients with no positive prognostic factors (PS0) had significantly better 10-year survival rates compared to those with one or more positive factors (PS1, PS2), indicating the importance of these factors in predicting patient outcomes.
Article Synopsis
- Salivary duct carcinoma (SDC) is an aggressive salivary gland cancer, and recent advancements in immunotherapy targeting immune checkpoints (like PD1 and CTLA4) show promise for treatment.
- * The study analyzed 175 SDC cases, focusing on various immune markers and their correlation with tumor behavior, indicating that high levels of certain markers (CD8, PD-L1, etc.) relate to more aggressive cancer features and worse outcomes.
- * Interestingly, there were no cases with microsatellite instability (MSI-high), suggesting that a mix of immune activity in SDC may hinder effective T-cell function and highlight potential strategies for immune checkpoint combination therapies.*
Approximately 60% of adenoid cystic carcinoma (AdCC) cases are positive for MYB::NFIB or MYBL1::NFIB, whereas MYB/MYBL1 oncoprotein, a key driver of AdCC, is overexpressed in most cases. Juxtaposition of superenhancer regions in NFIB and other genes into the MYB/MYBL1 locus is an attractive oncogenic hypothesis for AdCC cases, either negative or positive for MYB/MYBL1::NFIB. However, evidence supporting this hypothesis is insufficient.
View Article and Find Full Text PDFBackground/aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, no large-scale retrospective real-world data are available. This retrospective study aimed to examine the efficacy and safety of pembrolizumab in multiple facilities.
View Article and Find Full Text PDFMolecular targets and predictive biomarkers for prognosis in salivary duct carcinoma (SDC) have not been fully identified. We conducted comprehensive molecular profiling to discover novel biomarkers for SDC. A total of 67 SDC samples were examined with DNA sequencing of 464 genes and transcriptome analysis in combination with the clinicopathological characteristics of the individuals.
View Article and Find Full Text PDFBackground: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown.
Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled.
Background: Immune checkpoint inhibitors (ICIs) improve clinical outcomes in various cancers, but sometimes induce autoimmune adverse effects, including myocarditis, which is the most serious complication. There are many reports on ICI-induced myocarditis; however, only a few prospective surveillance reports exist. Therefore, we developed a prospective screening protocol and performed monitoring clinically suspected myocarditis in every patient treated with ICIs.
View Article and Find Full Text PDFBackground: Polymorphous adenocarcinoma is a common intraoral minor salivary gland carcinoma in Western countries but is extremely rare in Japan. The current study aimed to characterize the clinicopathological features and status of molecular alterations of polymorphous adenocarcinoma-associated genes, such as PRKD1/2/3, ARID1A, and DDX3X, in a large cohort of Japanese patients with polymorphous adenocarcinoma.
Methods: We examined the cases of 36 Japanese patients with salivary gland polymorphous adenocarcinoma and 26 cases involving histopathological mimics.
Background/aim: In patients with squamous cell carcinoma of the head and neck (SCCHN), delayed surgery can result in poorer postoperative function and prognosis due to the growth of the tumor and extended surgery. Further, delay may even make the tumor unresectable. To prevent tumor growth during the waiting period before surgery, S-1 has been administrated preoperatively at several facilities in Japan.
View Article and Find Full Text PDFArticle Synopsis
- A study investigated the effectiveness and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) using two different dosing strategies: 3 mg/kg and 240 mg/body.
- Researchers analyzed real-world data from 199 patients divided into the two dosing groups, assessing overall response rates, disease control rates, overall survival, and adverse events.
- The results showed no significant differences in efficacy or safety between the two doses, suggesting nivolumab can be effective at both dosing levels for R/M SCCHN patients.
Objective: Salivary duct carcinoma (SDC) is a highly aggressive and uncommon tumor arising not only but also in pleomorphic adenoma. Androgen receptor (AR)- and HER2-targeted therapy have recently been introduced for SDC as promising treatment options; however, no predictive biomarkers have yet been established. EZH2 and H3K27me3 are closely linked to the development and progression of various cancers, and EZH2 is also expected to be a desirable therapeutic target.
View Article and Find Full Text PDFBackground/aim: Prognostic factors of hypopharyngeal carcinoma have been reported previously. However, recurrent cases of this disease occurring within 6 months of treatment have been excluded or poorly documented in many studies. We aimed to evaluate the prognostic factors of hypopharyngeal carcinoma recurrence within 6 months.
View Article and Find Full Text PDFAims: To investigate the histological diversity of salivary mucoepidermoid carcinoma (MEC), its clinicopathological features, and its associations with CRTC1/3-MAML2 fusions.
Methods And Results: Salivary MEC cases (n = 177) were examined for CRTC1/3-MAML2 fusions, histological variants were classified, and tumours were graded according to four different grading systems. Adverse histological features considered to be unusual in MEC were also investigated.
Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a risk-stratification reporting system that was introduced in 2018. The objective of this multi-institutional study was to evaluate the utility of the MSRSGC in Japan.
Methods: In total, 1608 fine-needle aspiration samples with matching histologic diagnoses were retrieved from 12 large institutions in Japan.